Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: Bridging the gap between evidence and practice

Journal of Neurology

Volumn 248, Issue 7, 2001, Pages 551-557

  Frisoni, Giovanni B ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Alzheimer's disease; Clinical trials; Donepezil; Galantamine; Rivastigmine; Therapy

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; METRIFONATE; RIVASTIGMINE; TACRINE; XANOMELINE;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0034939380     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150170131     Document Type: Review

References (62)

1. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life
2. A Comparison of Observational Studies and Randomized. Controlled Trials
3. Behavioral disorders in Alzheimer disease: A transcultural perspective
4. Donepezil for mild and moderate Alzheimer's disease
5. Rivastigmine for Alzheimer's disease
6. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
7. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
8. Treating visual hallucinations with donepezil
9. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
10. Donepezil in treatment-resistant bipolar disorder
11. Why don't physicians follow clinical practice guidelines? A framework for improvement
12. Randomized, controlled trials, observational studies, and the hierarchy of research designs
13. Rivastigmine provides behavioural benefits to Alzheimer's disease patients residing in a nursing home: Findings from 26-week trial
14. Metri-fonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group
15. Cholinergic markers in elderly patients with early signs of Alzheimer disease
16. North of England evidence based guidelines development project: Guideline for the primary care management of dementia
17. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease
18. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group
19. Benefits of Donepezil on global function, behaviour, cognition, and ADLs in patients with moderate to severe Alzheimer's disease
20. Donepezil for the treatment of psychosis in dementia with Lewy bodies
21. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II-Pharmacologic therapy. Alzheimer's Disease Managed Care Advisory Council
22. Reimbursement of acetylcholinesterase inhibitors for Alzheimer's disease in Europe
23. The natural history of non demented cognitively impaired subjects:population data from Kung-sholmen Project
24. Behavioral syndromes in Alzheimer's disease: Description and correlates
25. Donepezil therapy in clinical practice: A randomized crossover study
26. A randomized, controlled trial of the effects of remote, intercessory prayer on outcomes in patients admitted to the coronary care unit
27. Comparison of prediction based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery
28. Overlap between pathology of Alzheimer disease and vascular dementia
29. Dementia with Lewy bodies: Response of delirium-like features to donepezil
30. Medicine based evidence, a prerequisite for evidence based medicine
31. Clinical predictors of course for Alzheimer patients in a longitudinal study: A preliminary report
32. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors
33. Donepezil for behavioural disorders associated with Lewy bodies: A case series
34. A controlled, crossover, randomized, double-blind trial of an anticholinesterase agent (donepezil) in patients with progressive supranuclear palsy
35. Guidelines on drug treatments for Alzheimer's disease
36. Can medical care improve memory in AD patients?
37. Treatment of Alzheimer's disease
38. Evidence-based medicine: An incomplete method for informing treatment choices
39. Efficacy of rivastigmine in dementia with Lewy bodies: A randomized, double blind, placebo-controlled international study
40. Clinical diagnosis of Alzheimer's disease: Report of NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
41. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up
42. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease
43. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
44. Healthcare rationing - Are additional criteria needed for assessing evidence based clinical practice guidelines?
45. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
46. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group
47. Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease
48. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group
49. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
50. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
51. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
52. The effect of rivastigmine on sleep in elderly healthy subjects
53. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
54. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study
55. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration
56. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group
57. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease
58. Donepezil for postoperative delirium associated with Alzheimer's disease
59. Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)